+86-576-88205808
Bozitinib (PLB-1001, CBT-101, APL-101, CBI-3103) is a highly selective ATP-competitive c-Met inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) selectively inhibits MET-altered tumor cells in preclinical models.
Copyright Copyright (C) 2018-2024 Taizhou Crene Biotechnology Co.,Ltd.
Address:Economic Developed Zone of Taizhou Zhejiang China